Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Responses in Moxifloxacin-containing TB Regimens
NCT01154959Phase 3Completed
- Sponsor
- National Institute for Research in Tuberculosis
- Start
- Feb 2010
- Primary completion
- Dec 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of moxifloxacin in pulmonary tuberculosis (TB) (5 arms), sponsored by National Institute for Research in Tuberculosis. Primary endpoint: Immune response to crude antigens (PPD, CFA) and defined antigens (ESAT-6, CFP-10) at 2 years. Started Feb 2010; status: completed.
02
Drugs
moxifloxacin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT01154959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01154959.